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Simple Summary: Emerging evidence suggests positive outcomes from the use of CBD as a cancer
treatment. CBD can relieve cancer pain and ease the side effects of chemotherapy; however, there is
less research about the mechanism of CBD’s anticancer effects. In this article, recent studies on the
efficacy and mechanisms of CBD’s anticancer effects in cell- and animal-based models and human
clinical studies are reviewed.
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Abstract: Cannabis sativa L. (Cannabis) and its bioactive compounds, including cannabinoids and noncannabinoids, have been extensively studied for their biological effects in recent decades. Cannabidiol
(CBD), a major non-intoxicating cannabinoid in Cannabis, has emerged as a promising intervention
for cancer research. The purpose of this review is to provide insights into the relationship between
CBD and cancer based on recent research findings. The anticancer effects of CBD are mainly mediated
via its interaction with the endocannabinoid system, resulting in the alleviation of pain and the
promotion of immune regulation. Published reviews have focused on the applications of CBD in
cancer pain management and the possible toxicological effects of its excessive consumption. In
this review, we aim to summarize the mechanisms of action underlying the anticancer activities of
CBD against several common cancers. Studies on the efficacy and mechanisms of CBD on cancer
prevention and intervention in experimental models (i.e., cell culture- and animal-based assays) and
human clinical studies are included in this review.
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1. Introduction

Publisher’s Note: MDPI stays neutral

Phytochemicals, including phytocannabinoids and non-phytocannabinoids, from
Cannabis sativa L. (Cannabis) have been investigated in many published studies in recent
years, especially since the legalization of Cannabis in many countries and regions. The
chemotypes of Cannabis can be classified by the levels of their two major phytocannabinoids,
namely, ∆9-tetrahydrocannabinol (THC, potentially intoxicating) and cannabidiol (CBD,
non-intoxicating). Cannabis sp. with low THC content (<0.4%) but high CBD levels is known
as hemp or industrial hemp, and is generally grown for industrial purposes (e.g., textiles,
rope, clothing, biofuel, and animal feed). Cannabis sp. with high THC content is cultivated
for medical applications and/or recreational use [1]. Cannabis plants are easy to cultivate,
as they do not require a specific type of soil; however, the soil should be at a neutral pH or
slightly alkaline [1]. Nitrogen is the main component in the soil that interacts with Cannabis
plants and contributes their THC content [1]. Cannabis sp. has evolved as a potential energy
crop, which is a crop grown for use in the generation of energy or the production of fuels.
For example, bioethanol cannabinoids have high biomass content, high land use efficiency,
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low nutrient requirements, and no pesticide demand, and they can improve the health of
soil with organic matter. They can also be effectively grown in diverse climates and can be
used in organic crop rotation [2]. Moreover, phytocannabinoids are extracted from Cannabis
plants and used to obtain various potential health benefits—including cancer treatment
and pain management [3].
CBD is a major bioactive, non-intoxicating cannabinoid in Cannabis plants. Many
Cannabis strains contain higher amounts of CBD than THC [4]. Emerging evidence suggests
positive outcomes when using CBD as a cancer treatment. One of the major mechanisms
of CBD’s anticancer effects is attributed to its interactions with the endocannabinoid
system (ECS), resulting in the alleviation of pain as well as the promotion of immunecell regulation [3]. The best known mechanism of action of cannabinoids (i.e., CBD) is
the mediation of endocannabinoid receptors. Cannabinoids may exert their anticancer
effects, as well as many of their other biological activities, primarily by binding to a group
of G protein-coupled receptors, known as type 1 and 2 cannabinoid receptors (CB1 and
CB2, respectively) [5]. CB1 and CB2 receptors can both exert anti-inflammatory, proapoptotic, and antiproliferative effects, which may help fight against cancer [6]. The
differences between these receptors are due to where they are distributed in the body [6].
CB1 receptors are found mainly in relation to the nervous system, at the ends of axons,
where they are able to inhibit neurotransmitter action and improve with management of
pain [6]. CB2 receptors, on the other hand, are highly expressed in peripheral tissues and
related to immune functions. CB2 receptors are involved in the control and regulation of
cytokinesis in the immune cells, ultimately helping with anticancer factors relating to cell
division, such as antiproliferation [6]. CB1 receptors have also been reported to regulate
various biological functions, such as appetite, metabolism, and body weight [7], which
can be helpful when they are used as treatments for chemotherapy-associated symptoms.
Moreover, the ECS is strongly involved in neuropsychiatric symptoms and disorders, such
as anxiety and depression [8], which are frequent problems for cancer patients [9]. THC
exerts psychotropic effects due to its high affinity with cannabinoid receptor (CB1) in the
brain, whereas non-psychotropic cannabinoids, such as CBD, have a lower affinity with
CB1, which can be activated to promote the positive effects of CBD [10]. In fact, CBD has a
lower affinity with both CB1 and CB2 receptors compared to THC. The anti-proliferative
effects of CBD and CBD-enriched extracts against cancer cells are associated with their
pro-apoptotic effects and their ability to activate the CB2 receptor [11]. CBD behaves as an
agonist of transient potential vanilloid (TRPV) receptors (type 1 and type 2) with no noxious
effects [11,12]. TRPV1 and TRPV2 channels are involved in nociception and thermosensing;
however, they are aberrantly expressed in several tumor types [13]. Emerging evidence
suggests that the activation of TRPV1 by a natural agonist (i.e., capsaicin) contributes to its
anticancer effects [14].
One way in which cannabinoids have been clinically used in cancer treatment is
through an oromucosal spray containing THC and CBD. This spray was used in cancer
patients with severe pain that was not resolved by applying typical opioid therapy [15].
Another study found that the pain relief offered by THC and CBD oromucosal spray
lasted over time, suggesting that no tolerance was built and that the dose did not need
to be increased after a period of time [16]. A more effective cannabinoid-based pain
reliever for cancer-related pain was found to be a THC:CBD combination, which was
more efficacious compared to THC alone [11]. When gauging patients’ acceptance of
CBD treatments for chemotherapy side effect reduction, it was found that the majority
of cancer patients preferred THC:CBD over placebo and that no serious side effects or
events occurred as a result of the THC:CBD co-treatment [11]. Published reviews have
focused on the application of cannabinoids in cancer pain management and their possible
toxicological effects with excessive consumption. Common side effects include somnolence,
nausea, dizziness, dry mouth, disorientation, euphoria, anxiety, and hallucination, as well
as some more severe adverse events, such as memory or cognitive problems, addiction,
and exacerbation or the provocation of mental disorders and pre-existing heart disease [17].
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It should be noted that the side effects associated with cannabinoids or Cannabis vary from
person to person (i.e., genetics, environmental factors, pre-existing conditions, etc.) and
are largely dependent on the drug dosage/frequency and cannabinoid constituents [17].
Specifically, toxicological effects are mostly associated with the high dose consumption
of THC, whereas CBD is thought to alleviate some of these adverse events. For example,
CBD is found to facilitate learning and ameliorate psychosis and anxiety [18]. Thus, in
the current review, our particular interest is in CBD as a non-intoxicating cannabinoid.
In this review, we sought to summarize the detailed mechanisms of action underlying
the anticancer activities of CBD on the four most common cancer types, i.e., lung, breast,
prostate, and colorectal cancer [19]. Recent studies that include relevant information about
the efficacy and mechanisms of action of CBD on cancer in cell culture and animal studies
are reviewed in this article.
2. General Characteristics of CBD in Cancer
The non-intoxicating nature of CBD is of importance because it allows greater patient
acceptance as a form of cancer treatment. Non-intoxicating cannabinoids, including CBD,
which are generally associated with less dramatic, non-intoxicating side effects, have been
used more frequently in cancer management in recent years [20]. CBD is generally well
tolerated and has a favorable safety profile [21]. The known beneficial effects of CBD on
cancer include tumor cell repression, the relief of cancer-related pain, and the reduction of
chemotherapy effects, such as nausea and vomiting [22]. Various cannabinoids have been
found to attenuate cell proliferation in different cancer cell lines. Despite their structural
similarity, cannabinoids may have different pharmacological effects and contributions. In a
study that compared the inhibitory effects of CBD, cannabichromene (CBC), cannabigerol
(CBG), and tetrahydrocannabivarin on cancer cells’ growth, it was found that CBD had the
greatest anti-proliferative effects against prostate cancer cells [23].
Apart from having effects against cancer cells, CBD in combination with THC has
been shown to be a promising treatment for cancer pain. For example, a clinical study
suggested that a THC:CBD combination was an efficient treatment for pain relief in cancer
patients compared to THC alone [16]. Patients also responded to novel combinations of
cannabinoids when opioid therapy treatment was insufficient [24]. In a follow-up study of
a three-arm clinical trial, patients were able to self-titrate nabiximols, a CBD:THC combination oral mucosal spray, to their preferred level for analgesia and comfort. In addition, lower
levels of cancer-related pain, as well as of insomnia and fatigue, were reported [24]. Notably,
these cancer patients were able to stay at the same or similar dose without increasing the
dosage, and the analgesic effect of the spray treatment remained at the same level [24].
Overall, these clinical studies showed positive outcomes of the long-term use of cannabinoids as analgesic treatments for cancer-related pain. Cannabinoids can also be used to
reduce the adverse effects associated with chemotherapy. When compared to a placebo for
reducing chemotherapy-induced nausea and vomiting, a CBD:THC combination showed
significant improvement. Some side effects occurred along with the cannabinoids, such as
dizziness and disorientation, but there were no severe adverse effects and the treatment
was tolerated well [12].
Although the efficacy of CBD or co-treatment with CBD and other cannabinoids in
alleviating cancer pain and the side effects associated with chemotherapy were assessed in
clinical trials, preclinical models were mostly used to evaluate the direct anticancer effects
of CBD. This review focuses on the summary of studies published in recent years on the
efficacy and mechanisms of action of CBD against four cancers: lung, breast, prostate,
and colorectal cancer (Table 1). These four types of cancer were selected because they are
the most common causes of cancer cases and deaths in the United States [19], as well as
globally [25].
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Table 1. Anticancer studies of CBD.
Cancer Type

Lung Cancer

Dosage/
Treatment

Effects

Non-small cell lung
cancer (NSCLC) A549,
H358, and H460 cell
lines, and
human-derived NSCLC
cells

Up to 3 µM CBD

In NSCLC cell lines: ↓ Intercellular
adhesion molecule-1 (ICAM-1)-dependent
cell invasion; ↑ ICAM-1 and matrix
metalloproteinases-1 (TIMP-1) via
cannabinoid receptors, transient receptor
potential vanilloid 1 (TRPV1), and p42/44
mitogen-activated protein kinase (MAPK)
In primary NSCLC cells: ↓
ICAM-1-dependent cell invasion; ↑
ICAM-1 and TIMP-1 expression, CBD
showed comparable anti-invasive efficacy
to THC (3 µM)

Athymic nude mice
xenografted with A549

5 mg/kg CBD by
intraperitoneal
injection

↓ Tumor size and number of metastatic
nodules; ↑ ICAM-1 and TIMP-1
expression

A549, H460, and H358

Up to 1 µM CBD

↓ Cell invasion, plasminogen activator
inhibitor-1 (PAI-1) via CB1, CB2, and
TRPV1 receptors

Athymic nude mice
xenografted with A549

5 mg/kg CBD by
intraperitoneal
injection

↓ Tumor size, PAI-1 protein expression

A549

10 µM CBD

↓ Cell invasion; ↑ TIMP-1, p42/44, and
p38 MAPKs via CB1, CB2, and TRPV1
receptors

A549-xenografted nude
mice

5 mg/kg CBD by
intraperitoneal
injection

↓ Number of metastatic nodules

A549 and H460, and
primary cells from a
lung cancer patient

3 µM CBD

↓ Cell viability; ↑ apoptosis,
cyclooxygenase-2 (COX-2) and PPAR-γ,
COX-2-dependent prostaglandins,
PPAR-γ–dependent apoptotic cell death

A549-xenografted nude
mice

5 mg/kg CBD by
intraperitoneal
injection

↓ Tumor size and CD31 (vascularization
marker); ↑ COX-2 and PPAR-γ

NSCLC A549 and H460
cell lines and human
derived metastatic lung
cancer cells

3 µM CBD

↑ Adherence to and lysis by
lymphokine-activated killer (LAK) cells,
ICAM-1 expression

[30]

NSCLC cell lines A549,
H460, H1792

Tetrahydrocannabinol
(THC) 30 µm,
cannabidiol (CBD)
30 µm, and
combination THC:CBD
10 µm each

All treatments: ↓ cancer cell proliferation,
epithelial-to-mesenchymal transition
(EMT), epidermal growth factor
(EGF)-induced cell migration
THC:CBD combination: ↓ epidermal
growth factor receptor (EGFR) gene

[31]

Up to 48 µM CBD;
10 µM CBD for
treatment of stem cell
spheres

↓ Cell viability, stem cell sphere formation,
expression of cancer stem cell genes
(SOX2, POU5F1, CD44, or PROM1),
mitochondrial membrane potential; ↑ cell
death, caspase 3/7 protein, expression of
apoptotic genes (TP53, CDKN1A, BAD,
BCL2, BAX, or BAK1), levels of reactive
oxygen species (ROS)

[32]

Model

A549 and H1299
NSCLC cell lines and
H69 small cell lung
cancer (SCLC) cell line

Reference

[26]

[27]

[28]

[29]
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Table 1. Cont.
Cancer Type

Breast Cancer

Prostate Cancer

Dosage/
Treatment

Effects

Cisplatin-resistant (CR)
NSCLC cell lines H460
and A549

Up to 90 µM CBD

↓ Cell viability, nuclear factor erythroid
2-related factor 2 (NRF-2) expression; ↑
apoptosis, ROS, sphere formation and
protein expression of Snail, Nanog, and
Vimentin

NSG mice injected with
H460-CR cells

10 mg/kg CBD by
intraperitoneal
injection

↓ Tumor progression and metastasis

MCF7 (estrogen
receptor-positive) and
MDA-MB-231
(triple-negative)

20 µM CBD

↓ Cell viability of both MCF7 and
MDA-MB- 231; ↑ Endoplasmic reticulum
stress, unfolded protein response (UPR)
activation, intracellular ROS and Ca2+
accumulation via the activated TRPV1
receptor in the MCF7

[34]

MCF7

Up to 20 µM CBD

↓ Bound NAD(P)H; ↑ mitochondrial
concentrations of ROS and Ca2+

[35]

Estrogen
receptor-positive (ER+)
aromataseoverexpressing
MCF-7aro

Up to 20 µM CBD

↓ Cell viability, aromatase activity, ERα
levels, cell cycle progression; ↑ autophagy,
apoptosis, ERβ levels

[36]

MCF7, MDA-MB-231,
T47D, and SK-BR-3

Up to 7 µM CBD

↓ Cell viability, angiogenesis, stemness,
hypoxia-induced factor-1α (HIF-1α)
expression through Src/von
Hippel–Lindau tumor suppressor protein
(VHL) signaling, Slug and Vimentin
(EMT-related proteins)

[37]

MDA-MB-231 and
MDA-MB-468
(triple-negative)

Up to 5 µM CBD in 2D
cultures and up to
50 µM in 3D cultures

↓ Cell viability (CBD had greater IC50
values in 3D than 2D), fibronectin,
vimentin, and integrins-α5, -β5, and -β1,
autophagy

MDA-MB-468

Up to 5 µM CBD in
combination with
doxorubicin (DOX)

↑ DOX sensitivity in cancer cells, caspase
9; ↓ LOX and integrin-α5

MDA-MB-231 cells and
female nude mice
injected with
MDA-MB-468 cells

CBD-loaded
extracellular vesicles (5
mg/kg)

↑ DOX sensitivity in cancer cells and
xenograft tumors, caspase 9, and BAX; ↓
interleukin-17 (IL-17), NF-κB, TGF-β, Bcl2
and mTOR

[39]

MCF7

38.42–64.6 µM CBD in
combination with DOX,
docetaxel, paclitaxel,
vinorelbine, and
7-ethyl-10hydroxycamptothecin

Enhanced effects were observed with the
combination of CBD and all
chemotherapeutic drugs, while the
strongest synergism was found between
CBD and vinorelbine and
7-ethyl-10-hydroxycamptothecin; ↑
apoptosis

[40]

Androgen receptor
(AR)-positive prostate
cancer cell line LNCaP

Up to 15 µM CBD

↓ Cell proliferation; ↑ phosphatases and
phosphatase-dependent apoptosis, but
cannabinoid receptor independent

[41]

Model

Reference

[33]

[38]
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Table 1. Cont.
Cancer Type

Colorectal
Cancer (CRC)

Dosage/
Treatment

Effects

Reference

AR-positive (LNCaP
and 22RV1) and
AR-negative (DU-145
and PC-3) cells

1–10 µM CBD

↓ Cell viability and AR (in LNCaP and
22RV1 cells); ↑ apoptosis, markers of
intrinsic apoptotic pathways
(p53-up-regulated modulator of apoptosis
(PUMA), C/EBP homologous protein
(CHOP) and intracellular Ca2+) partly
due to TRPM8 antagonism, p53 (in
LNCaP cells), and ROS

[23]

PC-3

1 and 5 µM CBD

↓ Exosome and microvesicle (EMV)
release, CD63 exosomal marker,
prohibitin, and STAT3

[42]

SW480

Up to 15 µM CBD

↓ Cell proliferation; ↑ phosphatases and
phosphatase-, CB1/CB2-dependent
apoptosis

[41]

10 µM CBD

↓ Cell proliferation via CB1, TRPV1, and
PPARγ receptors, Akt activation, and
DNA damage caused by an oxidative
insult
[43]

CRC induced by
azoxymethane (AOM)
in male ICR mice

1 and 5 mg/kg CBD by
intraperitoneal
injection

1 mg/kg: ↓ AOM-induced aberrant crypt
foci (AFC), polyp and tumor formation,
and Akt activation; ↑ apoptoic protein
cleaved caspase-3
5 mg/kg: ↓ AOM-induced polyp
formation

DLD-1 and HCT116

Up to 5 µM CBD

↓ Cell proliferation via CB1 receptor

[44]

HCT116

1 and 2.5 µM CBD

↓ Adhesion of HCT116 cells onto
endothelial cells, invasiveness, migration
via G protein-coupled receptor 55 (GPR55)

[45]

6 µM CBD

↓ Cell viability; ↑ apoptosis by regulating
pro- and anti-apoptotic proteins (CHOP,
inositol requiring enzyme-1α (RE1α),
phosphorylated protein kinase RNA-like
ER kinase (PERK), etc.), in a
Noxa-and-ROS-dependent manner

Model

Caco-2 and HCT116

HCT116 and DLD-1

BALB/c nude mice
injected with HCT116
Luc+ cells (a
luminescent cell line
derived from HCT116)

HCT116, HT29, and
DLD-1

Oxaliplatin-resistant
DLD-1 and colo205

[46]

10 and 20 mg/kg CBD
by intraperitoneal
injection

20 mg/kg ↓ tumor size; ↑ apoptosis and
Noxa expression

4 µM CBD

↓ Cell viability; ↑ apoptosis by regulating
pro- and anti-apoptotic proteins (CHOP,
PERK, death receptor DR5 expression by
ER stress, etc.), TNF-related
apoptosis-inducing ligand
(TRAIL)-induced apoptosis

[47]

4 µM CBD

↓ Cell proliferation, nitric oxide synthase 3
(NOS3), nitric oxide (NO), AMP-activated
protein kinase (AMPK), TOR, and Akt; ↑
autophagic markers LC3 and p62, ROS
via superoxide dismutase 2 (SOD2)
causing mitochondrial dysfunction

[48]
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Table 1. Cont.
Cancer Type

Model

BALB/c mice injected
with CT26 (mouse CRC
cells)

HT-29

Dosage/
Treatment

Effects

Reference

1 and 5 mg/kg CBD by
intraperitoneal
injection

↓ Tumor size, cellular pleomorphism,
vascular endothelial growth factor
(VEGF), serum levels of IL-6 and IL-8
(5 mg/kg), and malondialdehyde (MDA);
↑ apoptosis, SOD (5 mg/kg), glutathione
peroxidase (GPx) and glutathione
reductase (GR) activity, and total
antioxidant capacity

[49]

30 µM CBD

↓ Cell viability, glutathione
(GSH)-to-oxidized-glutathione (GSSG)
ratio, ascorbic acid (AA), catalase (CAT),
and GR and GPx activity; ↑ MDA and
necrosis

[50]

3. Efficacy and Mechanism of CBD on Cancer
3.1. Lung Cancer
One of the most frequently studied cancer types related to CBD treatment is lung
cancer, which is the leading cause of cancer death in the United States [19]. The majority
(~84%) of lung cancers are non-small cell lung cancer (NSCLC), and the rest are small cell
lung cancer (SCLC; ~13%) [19]. In general, SCLC tends to grow and metastasize faster
than NSCLC. In a study using lung cancer cell lines, including A549, H358, and H460
NSCLC, low doses of CBD (up to 3 µM) significantly attenuated intercellular adhesion
molecule-1 (ICAM-1)-dependent cell invasion via cannabinoid receptors, TRPV1, and
p42/44 mitogen-activated protein kinase (MAPK) [26]. CBD (3 µM) also inhibited ICAM1-dependent cell invasion in two NSCLC-patient-derived primary lung tumor cell lines,
and its efficacy was comparable to that of THC at the same concentration [26]. In a
follow-up study using athymic nude mice xenografted with A549 cells, the injection of
CBD (5 mg/kg) significantly decreased the size of xenografted tumors and the number
of metastatic nodules in the lungs, with ICAM-1 and TIMP-1 as the key molecular targets
of the anti-invasive mechanism of CBD [26]. In A549, H460 NSCLC cells, and metastatic
cells derived from a lung cancer patient, CBD (3 µM) elevated the susceptibility of these
lung cancer cells to lymphokine-activated killer (LAK) cell-mediated tumor-cell killing in
an ICAM-1-dependent manner [30]. Ramer et al. conducted several other cell cultures
(using A549, H460, and H358 cells, primary lung cancer cells) and animal-based (A549xenografted nude mice) studies, in which they found that low doses of CBD (i.e., up to
10 µM in cells and 5 mg/kg in mice) suppressed cell growth and invasiveness, shrink tumor
size, and decrease the number of metastatic nodules [27–29]. The anticancer effects of CBD
were mainly attributed to the inhibition of plasminogen activator inhibitor-1 (PAI-1) and
the activation of TIMP-1, p42/44 and p38 MAPKs, cyclooxygenase-2 (COX-2)-dependent
prostaglandins, and PPAR-γ–dependent apoptotic cell death. These reports also suggested
that CB1, CB2, and TRPV1 receptors played important roles in the anti-invasive activity of
CBD [27–29].
Drug resistance continues to be a principal factor contributing to therapeutic failure
in cancer patients. CBD was found to suppress the growth and metastasis of cisplatinresistant NSCLC [33]. Misri et al. reported that CBD at higher concentrations (>10 µM)
significantly reduced the viability of cisplatin-resistant NSCLC cells, stem-cell sphere
formation, and stemness gene expression, accompanied by the activation of apoptosis and
reactive oxygen species (ROS) [33]. They also found that CBD mediated its anticancer
effects in part via an ion channel receptor, TRPV2, whose expression correlated with better
overall survival for lung cancer patients [33]. In their follow-up study using NSG mice
subcutaneously injected with cisplatin-resistant H460 cells, the injection of CBD (10 mg/kg)
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significantly diminished tumor progression and metastasis and suppressed cancer stem
cell properties [33]. The upregulation of ICAM-1 was found in several types of cancer,
such as breast and lung cancer—the major cancer killers. ICAM-1 plays a key role in
tumor progression and prognosis, partly because it enhances the metastatic ability of
malignant tumors [51,52]. TRPV is a member of the transient receptor potential (TRP)
channels (which act as sensory mediators), which can be activated by endogenous ligands,
heat, and mechanical and osmotic stress. Several TRP channels, including TRPV1 and
TRPV2, are linked to cancer, especially at the later stages [53]. The deregulated expression
and/or activity of these channels are associated with cancer progression via abnormal cell
proliferation, differentiation, and death, resulting in the uncontrolled expansion of the
transformed cells [53]. Thus, these studies suggest that CBD could be used as a potential
therapeutic agent targeting ICAM-1 and TRPVs to attenuate the growth and metastasis of
malignant tumors.
In addition to NSCLC, CBD was able to suppress the growth of SCLC. CBD (up to
48 µM) significantly reduced the cell viability of NSCLC (A549 and H1299) and SCLC
(H69) cells [32]. Furthermore, CBD decreased the cancer stem cell spheres of both NSCLC
and SCLC. When these three cell lines were treated with 10 µM of CBD, sphere formation
and the expression of cancer stem cell genes (SOX2, POU5F1, CD44, or PROM1) were
significantly decreased [32]. Moreover, CBD (10 µM) induced cell death by activating
caspases 3 and 7, elevated the expression of pro-apoptotic genes (TP53, CDKN1A, BAD,
BCL2, BAX, or BAK1) and the levels of ROS, and resulted in a loss of mitochondrial
membrane potential in both cancers [32]. Apoptosis, a programmed cell-death process, is a
target of anticancer therapy. Apoptosis is mainly regulated by the caspase and Bcl-2 families
of proteins [54]. Among caspase proteins, executioner caspases 3 and 7 play a critical role
in apoptosis. Once cleaved by initiator caspases, a series of hallmark features of apoptosis,
including membrane blebbing, cell shrinkage, the formation of apoptotic bodies containing
substances from dying cells, and the fragmentation of chromosomal DNA, are initiated
and ultimately result in cell death [55]. Several anticancer agents approved by the United
States Food and Drug Administration (FDA) either directly target apoptotic pathways
in cancer cells or indirectly affect apoptosis-dependent cell survival and/or proliferation
pathways [56]. Toxic levels of ROS in cells can induce apoptosis by activating pro-apoptotic
effectors, such as Bcl-2, cytochrome c, and JNK pathways [56]. Thus, the anticancer activity
of CBD can be partially attributed to its ability to induce ROS and, subsequently, apoptosis.
The suppressive effect of combinations of THC and CBD on lung cancer were also
examined. In a study using A549, H460, and H1792 NSCLC cell lines, the in vitro assessment of the anti-proliferative effects of THC and CBD separately and in combination
showed that THC (30 µM) and CBD (30 µM) significantly suppressed NSCLC cell proliferation through the inhibition of epithelial-to-mesenchymal transition (EMT) and epidermal
growth factor (EGF)-induced cell migration [31]. The THC:CBD combination (10 µM each)
was the most effective at inhibiting NSCLC cell proliferation and in downregulating the
gene expression of epidermal growth factor receptor (EGFR), which was not observed in
the treatments with cannabinoids alone [31]. EGFR and vascular endothelial growth factor
(VEGF), two independent but interrelated signaling proteins, are critical in the growth and
metastasis of tumors. Clinically, an array of anticancer drugs targeting these pathways, such
as Bevacizumab, Sorafenib, Cetuximab, Erlotinib, Gefitinib, and Panitumumab, has been
developed to treat cancer, either alone or in combination with chemotherapy [57]. Further
research on the potential synergistic effect of CBD and other cannabinoids or anticancer
treatments against lung cancer progression and its underlying mechanisms of action are
warranted, as the enhanced efficacy may lower the required dosage for each agent in the
combination, thereby leading to milder side effects [58,59].
3.2. Breast Cancer
Breast cancer is the most common cancer in women in the United States, excluding skin
cancers [19]. Breast cancer that has estrogen receptors is estrogen receptor-positive type,
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while the triple-negative type lacks the expression of estrogen, progesterone, and human
epidermal growth factor receptors that are commonly found in breast cancer cells. The
triple-negative type is considered the most aggressive clinical form of breast cancer [60]. It
accounts for 10–15% of all breast cancer cases [19]. Among all the cancer types, the inhibitory
effects of CBD are most frequently studied in breast cancer models [61]. Because the effect
and mechanisms of CBD in breast cancer have been well reviewed by Almeida et al. [61], in
this section, we focus on the studies published in the last three years. Similar to the findings
on lung cancer cells, the localization and expression of TRPV1 might play an important
role in CBD’s anticancer activity on breast cancer cells. In a study using MCF7, an estrogen
receptor-positive cell line, and MDA-MB-231, a triple-negative cell line, CBD (20 µM)
selectively targeted ROS-induced endoplasmic reticulum stress and unfolded protein
response (UPR) activation in MCF7, but not in MDA-MB-231 [34]. The elevated intracellular
ROS in MCF7 cells was induced by Ca2+ influx through the TRPV1 receptor [34]. Even
though CBD (20 µM) inhibited the growth of MDA-MB-231 cells, oxidative stress-induced
endoplasmic reticulum stress and UPR activation were not involved. This may have been
due to the different localization of the TRPV1 receptor in these two cell lines [34]; MCF7
cells express TRPV1 on the plasma membrane and in the cytosol, whilst MDA-MB-231
mainly express tit on the endoplasmic reticulum and Golgi apparatus [62]. Another study
using MCF7 cells showed that CBD was able to trigger a decrease in bound NAD(P)H
and an increase in the mitochondrial concentrations of ROS and Ca2+ , accompanied by
changes in mitochondrial morphology [35]. In estrogen receptor-positive breast cancer
cells that overexpressed aromatase (MCF-7aro), CBD (up to 20 µM) greatly suppressed cell
growth by disrupting cell cycle progression and inducing autophagy to promote apoptosis,
accompanied by inhibited aromatase activity and estrogen receptor α expression and
enhanced estrogen receptor β expression [36]. Notably, CBD (5–10 µM) exerted stronger
effects on most of these endpoints than THC and endocannabinoid anandamide, suggesting
CBD as a potential therapeutic agent for estrogen receptor-positive breast cancer [36].
In a study using four breast cancer cell lines (MCF7, MDA-MB-231, T47D, and SKBR-3), CBD (up to 7 µM) diminished the angiogenesis (blood vessel formation) and stem
cell-like properties of these breast cancer cells through the downregulation of hypoxiainduced factor-1α (HIF-1α) and Src/von Hippel–Lindau tumor suppressor protein (VHL)
signaling [37]. Similar to the finding in NSCLC cells [31], a low dose of CBD (2 µM) was
able to decrease the expression of the EMT-related proteins Slug and Vimentin in breast
cancer cells [37]. In addition to regular 2D cell cultures, the efficacy and mechanism of CBD
against breast cancer in 3D cultures was assessed by Surapaneni et al. [38]. Interestingly,
the IC50 values of CBD in 3D cultures of triple-negative breast cancer MDA-MB-231 and
MDA-MB-468 cells were much higher than in 2D cultures, reaching 20.18 and 33.85 µM,
respectively (vs. 3.22 and 3.31 µM in the 2D cultures, respectively) [38]. 3D cell cultures
generally mimic the in vivo settings of tumor microenvironments better than 2D cultures
due to the complexity and heterogeneity of tumor microenvironments, such as cell–cell
interactions, which could partially explain the higher IC50 of CBD in 3D cultures [38].
Chemotherapy is one of the most frequently applied cancer treatments. In recent
years, the potential synergistic effects of CBD and chemotherapeutic drugs against breast
cancer have also been evaluated [38–40]. Doxorubicin (DOX) is a chemotherapy drug that
is commonly used to treat many types of cancer, such as breast cancer, bladder cancer, and
lymphoma. However, it causes significant side effects, most notably cardiotoxicity, at high
doses [63]. Two recent studies reported that when combined with CBD, DOX could be
more effective than when administered alone [38,39]. When CBD (1–5 µM) was added
to 0.5–1 µM of DOX, an increase in anti-proliferative and pro-apoptotic effects was observed. Furthermore, the protein expression of caspase-9, an initiating caspase of intrinsic
apoptosis [64], was greatly increased with the combination treatment in MDA-MB-468
triple-negative breast cancer cells, and the effect was superior to either agent alone [38].
Their follow-up study fabricated extracellular vesicles encapsulated with CBD (CBD EVs)
through sonication for sustained release and improved intracellular and intratumoral
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uptake [39]. Importantly, CBD EVs sensitized MDA-MB-231 xenograft tumors to DOX
through the suppression of pro-inflammatory proteins and the activation of pro-apoptotic
markers [39]. In addition to DOX, Alsherbiny et al. evaluated the effects of a combination of CBD with four more chemotherapeutic drugs, including docetaxel, paclitaxel,
vinorelbine, and 7-ethyl-10-hydroxycamptothecin in MCF7 cells [40]. Enhanced effects
were observed with the combination of CBD (38.42–64.6 µM) and all the chemotherapeutic
drugs, while the strongest synergism was found between CBD, vinorelbine, and 7-ethyl-10hydroxycamptothecin. A major molecular mechanism underlying the synergistic effects
was the boosting of the pro-apoptotic activity of these chemotherapeutic drugs in MCF7
cells by the CBD [40]. The enhancement of anticancer efficacy by CBD may help to reduce
the required dosage of these drugs in chemotherapy, which, in turn, may alleviate their
adverse effects. Since triple-negative breast cancer cases typically have a poorer prognosis [60], CBD and/or its combination with chemotherapeutic drugs may offer additional
treatment options for patients.
3.3. Prostate Cancer
Prostate cancer is the second leading cause of cancer death in men in the United States,
behind lung cancer [19]. Compared to breast, lung, and colorectal cancer, the protective
effect of CBD against prostate cancer was examined only in a small number of studies.
The androgen receptor (AR) plays a complicated, yet vital, role in the normal function of
the prostate, as well as in the progression of prostate cancer. AR-negative prostate cancer
is generally linked with a more unfavorable prognosis than the AR-positive type [65]. A
cell-culture study using the AR-positive prostate cancer cell line, LNCaP, suggested that
CBD (up to 15 µM) was successful at initiating the apoptosis of cancer cells and acting
as an antiproliferative agent [41]. Interestingly, the induction of apoptosis in LNCaP
cells was dependent on phosphatase, but was independent of cannabinoid receptors [41].
Petrocellis et al. studied the effects of CBD on AR-positive (LNCaP and 22RV1) and ARnegative (DU-145 and PC-3) cells and found that CBD (1–10 µM) significantly diminished
the viability of all four cell lines and the expression of AR in the LNCaP and 22RV1
cells [23]. Similar to the observations from many other studies, it was reported that the
anti-proliferative effects of CBD occurred through the activation of apoptosis, accompanied
by an increase in the markers of intrinsic apoptotic pathways (p53-upregulated modulator
of apoptosis (PUMA), C/EBP homologous protein (CHOP), and intracellular Ca2+ ), p53
(in the LNCaP cells only), and ROS [23]. The cellular stress mediators, the p53 family, and
their downstream transcriptional targets, such as PUMA and Noxa, play an important
role during apoptosis. Cellular stress, including oxidative stress, DNA damage stress,
and unfolded protein stress, typically lead to cell death and the clearance of stressed
cells [66]. CHOP is involved in endoplasmic reticulum stress-induced apoptosis, in which
the prolonged activation of unfolded endoplasmic reticulum proteins stimulates apoptotic
cell death via the upregulation of CHOP [67].
In another study on AR-negative PC-3 cells, a new mode of action underlying the
anticancer effect of CBD was reported. It was found that CBD (1 and 5 µM) inhibited the
release of exosome and microvesicle (EMV) and modulated EMV biogenesis, accompanied
by the reduced expression of exosomal marker CD63, prohibitin, and STAT3 in PC-3
cells [42]. EMV is released by most of the body’s cells and plays an important role in
intercellular communication by transferring genetic material (DNA, mRNA, miRNA, etc.)
and proteins. The increased release of EMV is associated with cancer through the delivery
of the oncogenic factors to normal cells, thereby leading to cancerous transformation [68].
Thus, as an EMV-inhibiting agent, CBD may sensitize malignant tumors to chemotherapy
and slow down cancer progression in vivo [68].
3.4. Colorectal Cancer (CRC)
CRC is the third most common cancer diagnosed in the United States [19]. The
inhibitory effect of CBD against CRC has been well studied in the past decade. Similar to
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lung, breast, and prostate cancer, the suppression of cell proliferation and xenograft tumor
growth, the induction of ROS and apoptosis, and the activation of CB and TRPV receptors
have been observed as a result of treating CRC with CBD. In SW480 [41], Caco-2 [43],
HCT116 [43–45], and DLD-1 [44] CRC cells, low doses of CBD (up to 15 µM) significantly
reduced cell proliferation through the direct or indirect activation of CB1, CB2, TRPV1,
PPARγ, and/or G protein-coupled receptor 55 (GPR55) receptors. However, these effects
may be cell line- and dose-dependent. A common antiproliferative mechanism of CBD
found across many CRC studies is its ability to regulate pro- and anti-apoptotic proteins
and mediators, thereby inducing the cellular apoptosis of CRC cells and tumors. For
example, CBD (6 µM) triggered the apoptosis of HCT116 and DLD-1 cells by regulating the
expression of CHOP, inositol-requiring enzyme-1α (RE1α), and phosphorylated protein
kinase RNA-like ER kinase (PERK) in a Noxa- and ROS-dependent manner [46]. The
transmembrane proteins, RE1α and PERK, are both involved in the upstream regulatory
pathways of CHOP. Unfolded endoplasmic reticulum proteins trigger the oligomerization
and autophosphorylation of RE1α and PERK, ultimately leading to the upregulation of
CHOP and the activation of apoptosis [67]. In HCT116, HT29, and DLD-1 cells, CBD
(4 µM) modulated the expression of CHOP, PERK, and death receptor DR5, and induced
TNF-related apoptosis-inducing ligand (TRAIL)-dependent apoptosis [47]. CHOP can
stimulate apoptosis through pathways including mitochondria-dependent death receptors.
Death receptor-mediated apoptosis is activated when death ligands, such as tumor necrosis
factor (TNF) and TRAIL, bind to death receptors, such as DR4 and DR5 [67].
The activation of cellular apoptosis was also observed in animal studies with CDB intervention. In colon-specific carcinogen azoxymethane (AOM)-treated mice, CBD (1 mg/kg)
diminished AOM-induced aberrant crypt foci (AFC), polyp, and tumor formation, and
Akt activation, as well as stimulating principal pro-apoptotic protein caspase-3 [43]. Akt is
also involved in CHOP-dependent apoptosis, acting as a direct modulator of caspases and
mitochondrial pro-apoptotic proteins [69]. In BALB/c nude mice injected with HCT116
Luc+ cells (a luminescent cell line derived from HCT116), CBD (20 mg/kg) significantly
suppressed the growth of xenograft tumors and elevated cellular apoptosis and Noxa
expression in the tumor tissue [46]. Another study, using BALB/c mice injected with CT26
(a mouse CRC cell line), also found that the inhibition of xenograft tumors by CBD (1 and
5 mg/kg) was accompanied by the induction of apoptosis and oxidative stress parameters,
including superoxide dismutase (SOD), glutathione peroxidase (GPx) and glutathione
reductase (GR) activity, and total antioxidant capacity [49]. Interestingly, oxidative stress
plays a biphasic role in carcinogenesis, partly depending on the concentration of ROS, with
high levels of ROS often being cytotoxic [70]. ROS is a potent apoptosis stimulator that
is capable of inducing the intrinsic mitochondrial pathway, the extrinsic death receptor,
and the endoplasmic reticulum stress pathway of apoptosis by altering the permeability
of the inner mitochondrial membrane and the activity of the mitochondrial permeability
transition pore complex (MPTP), leading to the release of cytochrome c and the activation of
caspases [70]. On the other hand, ROS can be pro-carcinogenic. Specifically, ROS is known
to cause DNA damage, which is typically involved in the pathogenesis of cancer [70]. In
Caco-2 and HCT116 cells, CBD (10 µM) protected cells against hydrogen peroxide-induced
oxidative damage to DNA molecules [43]. The role of CBD in ROS generation may be
contingent upon concentration, treatment time, and/or cell line, which warrants further
investigation.
In addition to apoptosis, necrosis is another major mechanism of cell death. The
major difference between these two cell death modes is that apoptosis is a highly regulated
physiological process, whereas necrosis is considered pathological. Autophagy is a cytoprotective process that can be induced as an adaptive response by endoplasmic reticulum
stress. It is linked to both apoptosis and necrosis, exerting a biphasic function that is either
pro-survival or pro-death [71]. The crosstalk between apoptosis, necrosis, and autophagy is
rather complex and beyond the scope of the current review. However, it is well recognized
that the modulation of cell death and autophagy has important implications for cancer
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pathogenesis and treatment. In HT-29 cells, CBD (30 µM) attenuated cancer cell growth and
induced necrosis, accompanied by diminished glutathione (GSH)-to-oxidized-glutathione
(GSSG) ratio, level of ascorbic acid (AA), activity of catalase (CAT), and GPx and GR, as well
as elevated levels of malondialdehyde (MDA) [50]. In this study, CBD induced oxidative
stress and ROS production in HT-29 cells, which appeared to consume GSH and suppress
the activity of the antioxidant enzymes CAT, GR, and GPx [50]. The effect of CBD on
autophagy was examined in oxaliplatin-resistant DLD-1 and colo205 cells [48]. Although
oxaliplatin is a standard chemotherapeutic drug for CRC treatment, patients often develop
resistance to oxaliplatin, which leads to treatment failure. In oxaliplatin-resistant DLD-1
and colo205 cell lines, CBD (4 µM) induced autophagic cell death by decreasing nitric oxide
synthase 3 (NOS3) activity and the activation of the AMP-activated protein kinase (AMPK),
TOR, and Akt signaling pathways [48], all of which are key signaling proteins involved in
tumorigenesis [72]. NOS3 mainly participates in the generation of nitric oxide (NO) and
has been found to promote the proliferation, angiogenesis, and invasiveness, as well as
suppress the apoptosis, of cancer cells [73]. ROS and the autophagic markers, LC3 and
p62, were increased by CBD via antioxidant SOD2, causing mitochondrial dysfunction [48].
Altogether, CBD sensitizes CRC cells to oxaliplatin treatment, which may help alleviate
drug resistance in chemotherapy.
Other mechanisms of CBD were also observed in CRC cells. For instance, CBD
(1 and 2.5 µM) significantly prevented the adhesion of HCT116 cells to endothelial cells
and suppressed their invasiveness and migration via the GPR55 receptor [45]. In BALB/c
mice injected with CT26 murine CRC cells, CBD (1 and 5 mg/kg) exerted suppressive effects
on tumor growth and cellular pleomorphism by diminishing the gene expression of VEGF, a
key mediator of angiogenesis in cancer, and serum levels of the proinflammatory cytokines,
IL-6 and IL-8 [49]. CBD’s inhibition of VEGF [49] and EGFR [31] might help explain its
protective effect against tumor invasiveness, migration, and metastasis. The proinflammatory cytokines, IL-6 and IL-8, are key mediators of inflammation. It is known that chronic
inflammation plays an essential role in all stages of tumorigenesis [74]. Specifically, poor
prognosis in CRC is correlated with the presence of proinflammatory cytokines [74]. The
anti-inflammatory effects of CBD have been demonstrated in a variety of experimental
settings [75], but their implication in cancer treatment requires further research.
4. Discussion and Conclusions
Although CBD shows promising positive effects on cancer management in numerous
preclinical studies and some human clinical trials, mechanistic studies on the efficacy of
CBD’s anticancer effects are still limited. Emerging evidence suggests that CBD and other
cannabinoid treatments may relieve cancer pain and ease the side effects of chemotherapy.
However, research on CBD as a cancer treatment and its underlying mechanisms of action,
especially in large clinical trials, are warranted. In addition to the limited knowledge on
the anticancer efficacy, mechanisms of action, and potential side effects of CBD in cancer
treatment, another major challenge in using CBD as a cancer therapy is that variations exist
among CBD-based products. The quality of Cannabis cultivation and the CBD constituents
of commercial products can vary significantly, as Cannabis contains more than 100 cannabinoids [17]. Synthetic, highly potent cannabinoid products that act as full cannabinoid
receptor agonists are also available on the market; many of these have been banned by the
U.S. government because they may cause severe illness, and even death [76,77]. Moreover,
different routes of drug administration and habits of consumption may also substantially
affect the pharmacokinetics of CBD, thereby altering its effectiveness. Similar to other
medicinal plants, the standardization of the concentration and composition of CBD-based
anticancer drugs is of great importance.
Through this review, we delineated the relationship between CBD treatment and its
anticancer effects. Based on mostly cell culture-based studies and a few animal models, it
is possible that complex and diverse molecular mechanisms are involved in the anticancer
activity of CBD. Among the most commonly reported are the activation of the CB1, CB2,
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